All In Biotech

Drug Trial Radar · NCT06554522

Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in Africa

Pragmatic Evaluation of Therapies to Enhance Respiratory Management in Preterm Infants in Africa

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,512 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,512

Planned (sponsor's estimate)

Start

Jan 1, 2025

Primary completion

Sep 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Indiana UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Coefficient Giving
First posted
Aug 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 hour, up to 24 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this pragmatic clinical trial is to learn if the drug surfactant given by a less invasive technique works to treat respiratory distress in preterm infants in low- and middle-income African countries where invasive ventilators are unavailable. It will also learn about the safety of the less invasive surfactant administration (LISA) technique. The main questions it aims to answer are: Does surfactant given by a less invasive surfactant administration technique improve survival in preterm infants in low- and middle-income countries? What medical problems do participants have when receiving surfactant given by the less invasive surfactant administration technique? Researchers will implement the less invasive surfactant administration technique and see if it works to treat respiratory distress in preterm infants compared to preterm who did not receive surfactant. Participants with respiratory distress who are being treated with continuous positive airway pressure and caffeine citrate will: Receive surfactant replacement therapy by the less invasive surfactant administration technique. Be monitored for complications Be followed throughout their hospitalization to determine their survival rate.

Conditions

  • Respiratory Distress Syndrome in Premature Infant
  • RDS of Prematurity
  • Surfactant Deficiency Syndrome Neonatal
  • Premature Birth

Interventions

  • SurfactantDrug

    Surfactant is instilled into the lungs through a thin catheter passed into the trachea during laryngoscopy while on continuous positive airway pressure (CPAP)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hospital SurvivalTime frame: Through hospitalization, an average of 6 months

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire Communautaire

    Bangui, Central African Republic · Not yet recruiting

  • Korle-Bu Teaching Hospital

    Accra, Ghana · Not yet recruiting

  • Komfo Anokye Teaching Hospital

    Kumasi, Ghana · Not yet recruiting

  • Tamale Teaching Hospital

    Tamale, Ghana · Not yet recruiting

  • Coast General Teaching & Referral Hospital

    Mombasa, Kenya · Not yet recruiting

  • Mama Lucy Kibaki Hospital

    Nairobi, Kenya · Not yet recruiting

  • Federal Teaching Hospital Ido-Ekiti

    Ido-Ekiti, Ekiti State, Nigeria · Recruiting

  • University of Ilorin Teaching Hospital

    Ilorin, Kwara State, Nigeria · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.